Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Avadel Pharmaceuticals ( (AVDL) ) has issued an announcement.
On January 12, 2026, Avadel Pharmaceuticals reported that its shareholders overwhelmingly approved the proposed acquisition of the company by fellow Irish drugmaker Alkermes plc, voting in favor of the scheme of arrangement at both a court-ordered scheme meeting and an extraordinary general meeting. Investors backed resolutions to implement the scheme, amend Avadel’s articles of association to ensure any new shares are captured by the transaction terms, and endorse on an advisory basis the compensation arrangements for named executive officers tied to the deal, clearing a key shareholder hurdle for the takeover and reinforcing support for Avadel’s integration into Alkermes’ portfolio.
The most recent analyst rating on (AVDL) stock is a Hold with a $23.50 price target. To see the full list of analyst forecasts on Avadel Pharmaceuticals stock, see the AVDL Stock Forecast page.
Spark’s Take on AVDL Stock
According to Spark, TipRanks’ AI Analyst, AVDL is a Neutral.
Avadel Pharmaceuticals is positioned for growth with strong revenue and cash flow improvements and positive corporate developments. However, the company faces significant challenges with profitability, as reflected in its valuation metrics. The technical indicators suggest a bullish trend, but the negative P/E ratio and lack of dividend yield weigh heavily on the overall score.
To see Spark’s full report on AVDL stock, click here.
More about Avadel Pharmaceuticals
Avadel Pharmaceuticals plc is an Ireland-incorporated biopharmaceutical company focused on developing innovative treatments that address limitations of existing therapies. Its lead commercial product, LUMRYZ, is the first and only once-at-bedtime, extended-release oxybate oral suspension approved by the U.S. Food and Drug Administration for treating cataplexy or excessive daytime sleepiness in narcolepsy patients aged seven and older.
Average Trading Volume: 2,964,576
Technical Sentiment Signal: Buy
Current Market Cap: $2.1B
For an in-depth examination of AVDL stock, go to TipRanks’ Overview page.